Evidence map›Paper›PMID 28946759›Full record

ReviewJournal of cardiovascular pharmacology and therapeutics2018

Cardiac Potassium Channels: Physiological Insights for Targeted Therapy.

Kamalan Jeevaratnam, Karan R Chadda, Christopher L-H Huang, A John Camm

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of cardiovascular pharmacology and therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 75 citations in OpenAlex.

  1. Article
  2. Article
  3. KPharmaceuticals (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Modulation of Redox-Sensitive Cardiac Ion Channels.Antioxidants (Basel, Switzerland) · 2025
    Review
  6. CNDP2: An Enzyme Linking Metabolism and Cardiovascular Diseases?Journal of cardiovascular translational research · 2025
    Review
  7. Unraveling the Plausible Role of Potassium Channel Openers in Alzheimer's Disease.Central nervous system agents in medicinal chemistry · 2025
    Article
  8. Review
  9. Review
  10. Modulation of NOX2 causes obesity-mediated atrial fibrillation.The Journal of clinical investigation · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Generation of cardiomyocytes from human-induced pluripotent stem cells resembling atrial cells with ability to respond to adrenoceptor agonists.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Article
  17. Small-conductance calcium-activated potassium channels in the heart: expression, regulation and pathological implications.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Review
  18. Article
  19. Article
  20. Is space flight arrhythmogenic?Frontiers in physiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Kamalan Jeevaratnam1 Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.ORCID 0000-0002-6232-388X
Karan R Chadda1 Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.
Christopher L-H Huang3 Physiological Laboratory, University of Cambridge, Cambridge, United Kingdom.
A John Camm5 Cardiac Clinical Academic Group, St George's Hospital Medical School, University of London, Cranmer Terrace, London, United Kingdom.
University of Cambridge · GBUniversity of London · GBUniversity of Surrey · GB

Funding

British Heart FoundationMedical Research CouncilWellcome Trust
6 · The paper itself

Abstract

The development of novel drugs specifically directed at the ion channels underlying particular features of cardiac action potential (AP) initiation, recovery, and refractoriness would contribute to an optimized approach to antiarrhythmic therapy that minimizes potential cardiac and extracardiac toxicity. Of these, K

Indexed as

HeartHeart RateAction PotentialsAnimalsAnti-Arrhythmia AgentsDrug DevelopmentHeart DiseasesHumansMolecular Targeted TherapyMyocytes, CardiacPotassium Channel BlockersPotassium ChannelsAnti-Arrhythmia AgentsPotassium Channel BlockersPotassium Channelscurrentsdrug targetion channelphysiological mechanismspotassium channelsrepolarization

Identifiers

PMID28946759
PMCPMC5808825
OpenAlexW2759445263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.